一分钟看懂
这是一项关于恶性间皮瘤的I 期 / II 期研究，登记的药物或干预包括ISM6331，当前状态为招募中。登记地点显示中国郑州、上海、北京、广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
ISM6331 · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Henan Cancer Hospital · 郑州
- Shanghai Pulmonary Hospital · 上海
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
- Sun Yat-Sen University Cancer Center · 广州
公开的入选条件
- 1. Male or female participants with age ≥18 years at the time of signing the informed consent.
- 2. Histologically confirmed unresectable advanced or metastatic mesothelioma or other advanced solid tumors, who have failed standard therapy or for whom no effective standard therapy exists, participants for part 1 is regardless of the presence or absence of
- 3. Participants with malignant mesothelioma must have prior exposure to at least immune checkpoint therapy and platinum-based chemotherapy.
- 4. Presence of at least one evaluable lesion in Part 1 or one measurable target lesion in Part 2 according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) for participants with non-pleural mesothelioma or other solid tumors and modifi
- 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1.
- 6. Life expectancy of ≥12 weeks as judged by the investigator.
- 7. Adequate organ function as determined by medical assessment (within 7 days prior to the first dose of study treatment).
- 8. Capable of providing signed informed consent form (ICF) and complying with the requirements and restrictions listed in the ICF and in this study protocol.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06566079；登记信息更新于 2026-09-16。